Risankizumab receives FDA approval for pediatric use - NAPNAP
Skip to content
Member Network
PedsCE
SM
JPHC
Events
Store
APRN Jobs
Contact
Main Menu
I want to:
join or renew
register for an event
access student information
earn CE
get practice resources
Search for:
Member Network
PedsCE
SM
JPHC
Events
Store
APRN Jobs
Contact
Membership
Membership Types
Full
Student
Membership Programs
Recruit & Reward
Enterprise Membership
Group Membership
Corporate Circle
Dual Membership Program
Chapters
Chapter Guidelines
Shared Interest Groups
SIG Leader Resources
Students
Ways to Engage
Committees
Awards
Presidential Commendation
Volunteering
MemberDeals
TeamPeds Book Club
Membership FAQ
Continuing Education
PedsCE
SM
Continuing Education Opportunities
Call for Online Authors
NAPNAP Cares
TeamPeds Talks
Accredited Continuing Education Providers
Continuing Education FAQ
Students
Conferences & Events
Pediatric Virtual Symposium
National Conference
Certification Review Courses
Become Our Event Partner
TeamPeds Career Conversations
TeamPeds Experts Live
Advocacy
Advocacy Center
Advocacy in Action
Health Policy Agenda
Advocacy Resources
Child Health Policy Learning Collaborative
Inside the Beltway
Editions
News & Resources
News
Association Updates
Official Statements
Press Releases
NAPNAP Newsroom
Publications
Position Statements and White Papers
2022 Pulse of the Profession
NAPNAP Journal and Books
Career Resource Guide
Student Resources
Practice FAQ
Practice Resources
Clinical Practice Resources
Pediatric Clinical Trials
Overcoming Provider Burnout
Patient & Family Information
Research
Research Agenda
Advertisers & Media
About Us
About Pediatric Nurse Practitioners
NAPNAP’s Guiding Principles
Bylaws
NAPNAP Global Initiatives
Election Results
NAPNAP Executive Board
NAPNAP Staff
Advertisers & Media
50Forward
FAQ
How Do I…?
Membership FAQ
Continuing Education FAQ
Practice FAQ
Member Login
Membership
Membership Types
Full
Student
Membership Programs
Recruit & Reward
Enterprise Membership
Group Membership
Corporate Circle
Dual Membership Program
Chapters
Chapter Guidelines
Shared Interest Groups
SIG Leader Resources
Students
Ways to Engage
Committees
Awards
Presidential Commendation
Volunteering
MemberDeals
TeamPeds Book Club
Membership FAQ
Continuing Education
PedsCE
SM
Continuing Education Opportunities
Call for Online Authors
NAPNAP Cares
TeamPeds Talks
Accredited Continuing Education Providers
Continuing Education FAQ
Students
Conferences & Events
Pediatric Virtual Symposium
National Conference
Certification Review Courses
Become Our Event Partner
TeamPeds Career Conversations
TeamPeds Experts Live
Advocacy
Advocacy Center
Advocacy in Action
Health Policy Agenda
Advocacy Resources
Child Health Policy Learning Collaborative
Inside the Beltway
Editions
News & Resources
News
Association Updates
Official Statements
Press Releases
NAPNAP Newsroom
Publications
Position Statements and White Papers
2022 Pulse of the Profession
NAPNAP Journal and Books
Career Resource Guide
Student Resources
Practice FAQ
Practice Resources
Clinical Practice Resources
Pediatric Clinical Trials
Overcoming Provider Burnout
Patient & Family Information
Research
Research Agenda
Advertisers & Media
About Us
About Pediatric Nurse Practitioners
NAPNAP’s Guiding Principles
Bylaws
NAPNAP Global Initiatives
Election Results
NAPNAP Executive Board
NAPNAP Staff
Advertisers & Media
50Forward
FAQ
How Do I…?
Membership FAQ
Continuing Education FAQ
Practice FAQ
Member Login
Risankizumab receives FDA approval for pediatric use
Risankizumab receives FDA approval for pediatric use
By
/
June 29, 2026
←
Previous Napnap Item
Next Napnap Item
→
Website design and development by Americaneagle.com, Inc.
Login
Email Address
Password
Remember Me
Forgot your User ID? Click here
Forgot or do not have a password? Click here
New Users
Create a User Account
Become a Member
Scroll to Top
